Guo Benjie, Shen Yuting, Dai Ziying, Yimamu Kalibinuer, Sun Jianhua, Pei Lixia
Jiangsu Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China.
Front Endocrinol (Lausanne). 2024 Nov 27;15:1446827. doi: 10.3389/fendo.2024.1446827. eCollection 2024.
Insulin resistance (IR) is considered a major driver of the pathophysiology of polycystic ovary syndrome (PCOS), mediating the progression of hyperandrogenism and metabolic and reproductive dysfunction in patients with PCOS. Early detection of the risk of concurrent IR is essential for women with PCOS. To address this need, this study developed a predictive nomogram for assessing the risk of IR in women with PCOS, aiming to provide a tool for risk stratification and assist in clinical decision-making.
Patients with untreated PCOS-IR diagnosed in a single-center retrospective cohort study from January 2023 to December 2023 were included for nomogram construction and validation. The area under the ROC curve (AUC), calibration curve, Hosmer-Lemeshow (H-L) goodness-of-fit test, and decision curve analysis (DCA) were used to evaluate the nomogram's discrimination, calibration, and clinical decision performance. A risk stratification model based on the nomogram was then developed.
A total of 571 patients were included in the study; 400 patients enrolled before September 2023 were divided into the training and validation sets, and 171 patients enrolled later were used as the external validation set. The variables identified by logistic regression and the random forest algorithm-body mass index (BMI, OR 1.43), triglycerides (TG, OR 1.22), alanine aminotransferase (ALT, OR 1.03), and fasting plasma glucose (FPG, OR 5.19)-were used to build the nomogram. In the training, internal validation, and external validation sets, the AUCs were 0.911 (95% CI 0.878-0.911), 0.842 (95% CI 0.771-0.842), and 0.901 (95% CI 0.856-0.901), respectively. The nomogram showed good agreement between predicted and observed outcomes, and patients were categorized into low-, medium-, and high-risk groups based on their scores.
Independent predictors of untreated PCOS-IR risk were incorporated into a nomogram that effectively classifies patients into risk groups, providing a practical tool for guiding clinical management and early intervention.
胰岛素抵抗(IR)被认为是多囊卵巢综合征(PCOS)病理生理学的主要驱动因素,介导PCOS患者高雄激素血症以及代谢和生殖功能障碍的进展。对于PCOS女性而言,早期发现并发IR的风险至关重要。为满足这一需求,本研究开发了一种预测列线图,用于评估PCOS女性发生IR的风险,旨在提供一种风险分层工具并协助临床决策。
纳入2023年1月至2023年12月在单中心回顾性队列研究中确诊的未经治疗的PCOS-IR患者,用于列线图的构建和验证。采用ROC曲线下面积(AUC)、校准曲线、Hosmer-Lemeshow(H-L)拟合优度检验和决策曲线分析(DCA)来评估列线图的区分度、校准度和临床决策性能。然后基于列线图建立了一个风险分层模型。
本研究共纳入571例患者;2023年9月之前入组的400例患者被分为训练集和验证集,后来入组的171例患者用作外部验证集。通过逻辑回归和随机森林算法确定的变量——体重指数(BMI,OR 1.43)、甘油三酯(TG,OR 1.22)、丙氨酸转氨酶(ALT,OR 1.